Information Provided By: 
Fly News Breaks for June 15, 2018
CFRX
Jun 15, 2018 | 10:10 EDT
Pre-open, Chardan analyst Keay Nakae initiated ContraFect with a Buy and $2.80 price target saying he wants investors to focus on lead compound, CF-301, a novel enzyme-based antibiotic being developed against Staphylococcus aureus, a major cause of blood stream infections caused by methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) S aureus strains. CF-301, is a first-in-class, proprietary recombinant lysin. The analyst believes a successful result of the Phase 2 clinical trial could be a significant value event for the company.
News For CFRX From the Last 2 Days
There are no results for your query CFRX
